NO20082498L - Diarylurea for behandling av pulmonar hypertensjon - Google Patents

Diarylurea for behandling av pulmonar hypertensjon

Info

Publication number
NO20082498L
NO20082498L NO20082498A NO20082498A NO20082498L NO 20082498 L NO20082498 L NO 20082498L NO 20082498 A NO20082498 A NO 20082498A NO 20082498 A NO20082498 A NO 20082498A NO 20082498 L NO20082498 L NO 20082498L
Authority
NO
Norway
Prior art keywords
treatment
pulmonary hypertension
diarylurea
compositions
fluorophenoxy
Prior art date
Application number
NO20082498A
Other languages
English (en)
Norwegian (no)
Inventor
Bernd Riedl
Peter Sandner
Hanna Tinel
Joachim Hutter
Martina Klein
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of NO20082498L publication Critical patent/NO20082498L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20082498A 2005-11-10 2008-06-04 Diarylurea for behandling av pulmonar hypertensjon NO20082498L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05024509 2005-11-10
EP05027450 2005-12-15
EP06012234 2006-06-14
PCT/EP2006/010406 WO2007054216A1 (en) 2005-11-10 2006-10-30 Diaryl urea for treating pulmonary hypertension

Publications (1)

Publication Number Publication Date
NO20082498L true NO20082498L (no) 2008-08-07

Family

ID=37622057

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082498A NO20082498L (no) 2005-11-10 2008-06-04 Diarylurea for behandling av pulmonar hypertensjon

Country Status (18)

Country Link
US (1) US20100035888A1 (cg-RX-API-DMAC7.html)
EP (1) EP1948170A1 (cg-RX-API-DMAC7.html)
JP (1) JP5084736B2 (cg-RX-API-DMAC7.html)
KR (1) KR20080067000A (cg-RX-API-DMAC7.html)
AR (1) AR057849A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006312714A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0618522A2 (cg-RX-API-DMAC7.html)
CA (1) CA2628849A1 (cg-RX-API-DMAC7.html)
CR (1) CR9953A (cg-RX-API-DMAC7.html)
EC (1) ECSP088430A (cg-RX-API-DMAC7.html)
GT (1) GT200800058A (cg-RX-API-DMAC7.html)
IL (1) IL191178A0 (cg-RX-API-DMAC7.html)
NO (1) NO20082498L (cg-RX-API-DMAC7.html)
PE (1) PE20070806A1 (cg-RX-API-DMAC7.html)
SV (1) SV2009002900A (cg-RX-API-DMAC7.html)
TW (1) TW200733961A (cg-RX-API-DMAC7.html)
UY (1) UY29903A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007054216A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) * 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
ES2425739T3 (es) 2002-02-11 2013-10-17 Bayer Healthcare Llc Sorafenib-tosilato para el tratamiento de enfermedades caracterizadas por angiogénesis anormal
WO2004073778A1 (en) * 2003-02-21 2004-09-02 Resmed Limited Nasal assembly
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
ES2305808T3 (es) * 2003-05-20 2008-11-01 Bayer Healthcare Llc Diarilureas con actividad inhibidora de quinasas.
BRPI0412219B8 (pt) 2003-07-23 2021-07-27 Bayer Healthcare Llc compostos ômega-carboxi aril difenil uréia fluoro substituídos e composições farmacêuticas compreendendo os referidos compostos
CA2581843C (en) * 2004-09-29 2012-05-15 Bayer Healthcare Ag Thermodynamically stable form of bay 43-9006 tosylate
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP2129376B1 (en) * 2007-01-19 2013-07-24 Bayer HealthCare LLC Treatment of cancers with acquired resistance to KIT inhibitors
JP2011525503A (ja) * 2008-06-25 2011-09-22 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心不全を処置するためのジアリールウレア
CA2796744A1 (en) * 2010-04-17 2011-10-20 Bayer Healthcare Llc Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
MX2013003695A (es) 2010-10-01 2013-05-20 Bayer Ip Gmbh Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida.
WO2012125379A1 (en) * 2011-03-14 2012-09-20 Cellworks Research India Private Limited Compositions, process of preparation of said compositions and method of treating inflammatory diseases
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2425739T3 (es) * 2002-02-11 2013-10-17 Bayer Healthcare Llc Sorafenib-tosilato para el tratamiento de enfermedades caracterizadas por angiogénesis anormal
WO2003084543A1 (en) * 2002-04-10 2003-10-16 Virginia Commonwealth University Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
ES2305808T3 (es) * 2003-05-20 2008-11-01 Bayer Healthcare Llc Diarilureas con actividad inhibidora de quinasas.
BRPI0412219B8 (pt) * 2003-07-23 2021-07-27 Bayer Healthcare Llc compostos ômega-carboxi aril difenil uréia fluoro substituídos e composições farmacêuticas compreendendo os referidos compostos
EP1850852A4 (en) * 2005-02-22 2009-11-18 Cedars Sinai Medical Center USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO INCREASE THE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN DISEASE

Also Published As

Publication number Publication date
KR20080067000A (ko) 2008-07-17
JP2009514910A (ja) 2009-04-09
US20100035888A1 (en) 2010-02-11
CR9953A (es) 2008-10-08
AR057849A1 (es) 2007-12-19
JP5084736B2 (ja) 2012-11-28
PE20070806A1 (es) 2007-09-29
GT200800058A (es) 2010-02-23
EP1948170A1 (en) 2008-07-30
WO2007054216A1 (en) 2007-05-18
ECSP088430A (es) 2008-07-30
UY29903A1 (es) 2007-06-29
AU2006312714A1 (en) 2007-05-18
TW200733961A (en) 2007-09-16
SV2009002900A (es) 2009-04-28
BRPI0618522A2 (pt) 2011-09-06
CA2628849A1 (en) 2007-05-18
IL191178A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
NO20082498L (no) Diarylurea for behandling av pulmonar hypertensjon
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
NO20070994L (no) N-hydroksamid derivater og anvendelse derav
HRP20050663A2 (en) Malonamide derivatives as gamma-secretase inhibitors
LTC1793824I2 (lt) Naujos farmacinės kompozicijos, apimančios 4-(4-(3-(4-chlor-3-trifluormetilfenil)ureido)-3-fluorfenoksi)piridin-2-karboksirūgštį, hiperproliferacinių sutrikimų gydymui
MX2009006055A (es) Formas cristalinas del acido (3s)-3-[n-(n'-(2-terc-butilfenil)oxam il)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoi co.
NO20083836L (no) N-hydroksyakrylamidforbindelser
EA200870019A1 (ru) Лактамовые соединения и способы их применения
WO2013185112A8 (en) Pharmaceutical compositions for the treatment of cftr -mediated disorders
EA200702198A1 (ru) Фармацевтические составы
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
SE0403006D0 (sv) New compounds
NO20076405L (no) Anvendelse av 24-nor-UDCA
EA202090029A1 (ru) Твердая композиция карипразина для орального введения
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
EA200971087A1 (ru) Фармацевтические композиции и способ лечения острой мании
CL2004000806A1 (es) Compuestos derivados de quinazolinas, inhibidores de quinasa p38, composicion farmaceutica, procedimiento de preparacion, utiles para tratar artritis, enfermedad de crohn, alzheimer, asma, ataque al corazon, sepsis, infarto al miocardio y otras.
NO20070146L (no) 4-fenylpyrimidin-2-karbonitril-derivater
WO2008026048A3 (en) Stable injectable pharmaceutical compositions of docetaxel
NO20054876L (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
JP2012097036A5 (cg-RX-API-DMAC7.html)
DE602006008186D1 (de) Neues imprägnierverfahren einer textiloberfläche
NO20065835L (no) Medikamenter som inneholder N-sulfamoyl-N'-arylpiperaziner for profylakse eller behandling av overvekt og beslektede tilstander

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application